Sign In
Buy CDXC
$7.87
+0 (+0%)
At Close: Jun 17, 2025
Recent Price Trend in ChromaDex (CDXC) is Your Friend, Here's Why
09:50am, Thursday, 21'st Nov 2024
ChromaDex (CDXC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) with a focus on the science of healthy aging, announ
What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now?
01:01pm, Friday, 08'th Nov 2024
Does ChromaDex (CDXC) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
08:10am, Friday, 08'th Nov 2024
Investors target stocks that are witnessing a bull run. Some of the stocks seeing price strength are CDXC, SEZL, TILE, BGC, CORT.
ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide
08:32am, Thursday, 07'th Nov 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, today announc
ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue?
10:16am, Tuesday, 05'th Nov 2024
ChromaDex (CDXC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ChromaDex (CDXC) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Tuesday, 05'th Nov 2024
ChromaDex (CDXC) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through ou
ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript
02:48pm, Friday, 01'st Nov 2024
ChromaDex Corporation (NASDAQ:CDXC ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 PM ET Company Participants Ben Shamsian - IR Rob Fried - CEO Ozan Pamir - CFO Andrew Shao - SVP, Scientific
ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates
06:20pm, Thursday, 31'st Oct 2024
ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago.
ChromaDex Gears Up to Report Q3 Earnings: Here's What to Expect
12:46pm, Tuesday, 29'th Oct 2024
On CDXC's third-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its marketed product Niagen and updates on the pipeline.
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
08:32am, Monday, 28'th Oct 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced th
ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
08:32am, Thursday, 24'th Oct 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced tha
ChromaDex to Participate in the 17th Annual LD Micro Main Event
08:34am, Wednesday, 23'rd Oct 2024
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced tha
Are Medical Stocks Lagging ChromaDex (CDXC) This Year?
10:45am, Friday, 18'th Oct 2024
Here is how ChromaDex (CDXC) and Bioventus (BVS) have performed compared to their sector so far this year.
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CRN--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, announced today tha
